Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: Cross-cultural issues

Current Rheumatology Reports

Volumn 12, Issue 4, 2010, Pages 237-249

  Toloza, Sergio M A ^a   Jolly, Meenakshi ^b   Alarcón, Graciela S ^c  

^a Hospital San Juan Bautista   (Argentina)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

Cross cultural issues; Health related quality of life; Lupus; Quality of life; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE;

CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CULTURAL FACTOR; DEVELOPED COUNTRY; DISEASE ACTIVITY; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ETHNIC DIFFERENCE; HUMAN; LANGUAGE ABILITY; LUPUS ERYTHEMATOSUS NEPHRITIS; PATIENT ASSESSMENT; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SOCIAL ADAPTATION; SOCIAL STATUS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS; CLINICAL TRIAL (TOPIC); ETHNOLOGY; FEMALE; HEALTH STATUS; MALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; CROSS-CULTURAL COMPARISON; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955981467     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0110-5     Document Type: Review

References (55)

1. MH Liang SA Socher MG Larson PH Schur 1989 Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus Arthritis Rheum 32 1107 1118 10.1002/anr.1780320909 1:STN:280:DyaL1MznsVeltg%3D%3D 2775320
2. C Bombardier DD Gladman MB Urowitz, et al. 1992 Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 35 630 640 10.1002/art.1780350606 1:STN:280: DyaK383oslWrtg%3D%3D 1599520
3. DP Symmons JS Coppock PA Bacon, et al. 1988 Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG) Q J Med 69 927 937 1:STN:280:DyaK3c7jvFCgtg%3D%3D 3271336
4. DD Gladman MB Urowitz CH Goldsmith, et al. 1997 The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus Arthritis Rheum 40 809 813 10.1002/art.1780400506 1:STN:280:DyaK2s3psl2jug%3D%3D 9153540
5. V Strand D Gladman D Isenberg, et al. 2000 Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology Lupus 9 322 327 10.1191/096120300678828424 1:STN:280:DC%2BD3czosVemtw%3D%3D 10878722
6. JN Siegel 1999 Development of an FDA guidance document for clinical trials in SLE Lupus 8 581 585 10.1191/096120399680411425 1:STN:280: DC%2BD3c%2FjvVaiug%3D%3D 10568893
7. CA McHorney JE Ware Jr AE Raczek 1993 The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs Med Care 31 247 263 10.1097/00005650- 199303000-00006 1:STN:280:DyaK3s7ps1antA%3D%3D 8450681
8. J Thumboo V Strand 2007 Health-related quality of life in patients with systemic lupus erythematosus: an update Ann Acad Med Singapore 36 115 122 17364078 This is an interesting review of the literature on HRQoL and of the measures on how to improve it in patients with SLE
9. GS Alarcón G McGwin Jr A Uribe, et al. 2004 Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course Arthritis Rheum 51 465 474 10.1002/art.20409 15188335
10. DD Gladman MB Urowitz A Ong, et al. 1996 A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE) Lupus 5 190 195 10.1177/096120339600500305 1:STN:280:DyaK28zps1Ortw%3D%3D 8803889
11. DD Gladman MB Urowitz A Ong, et al. 1996 Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life Clin Exp Rheumatol 14 305 308 1:STN:280:DyaK28vgsFejtA%3D%3D 8809446
12. M Jolly 2005 How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 32 1706 1708 16142864
13. M Jolly TO Utset 2004 Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 13 924 926 10.1191/0961203304lu2034oa 1:STN:280:DC%2BD2M%2FhvFCrsA%3D%3D 15645747
14. R Aggarwal CT Wilke AS Pickard, et al. 2009 Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus J Rheumatol 36 1209 1216 10.3899/jrheum.081022 19369452 The psychometric properties of two preference-based generic HRQoL measures, the EQ-5D and SF-6D, among US patients with SLE were assessed and found to be satisfactory. Measures of disease activity and damage were found to be weakly correlated with HRQoL
15. The WHOQOL Group 1998 Development of the World Health Organization WHOQOL-BREF quality of life assessment Psychol Med 28 551 558 10.1017/S0033291798006667
16. SE Milligan DL Hom SP Ballou, et al. 1993 An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus J Rheumatol 20 972 976 1:STN:280:DyaK3szltlCqtQ%3D%3D 8350333
17. CS Burckhardt B Archenholtz A Bjelle 1993 Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis J Rheumatol 20 977 981 1:STN:280:DyaK3szltlCqug%3D%3D 8350334
18. AA Lash 1998 Quality of life in systemic lupus erythematosus Appl Nurs Res 11 130 137 10.1016/S0897-1897(98)80132-8 1:STN:280:DyaK1cvjtVWkuw%3D%3D 9757613
19. B Archenholtz CS Burckhardt K Segesten 1999 Quality of life of women with systemic lupus erythematosus or rheumatoid arthritis: domains of importance and dissatisfaction Qual Life Res 8 411 416 10.1023/A:1008915115370 1:STN:280:DyaK1MvgtlCqsg%3D%3D 10474282
20. KP Leong KO Kong BY Thong, et al. 2005 Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQoL) Rheumatology (Oxford) 44 1267 1276 10.1093/rheumatology/keh605 1:STN:280:DC%2BD2MrgtV2rtA%3D%3D
21. LC Doward SP McKenna D Whalley, et al. 2009 The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus Ann Rheum Dis 68 196 200 10.1136/ard.2007.086009 1:STN:280:DC%2BD1M%2FmsVyltg%3D%3D 18385276 The development and testing of a new instrument to measure QoL (L-QoL) in 93 adult SLE patients from the United Kingdom is described
22. K McElhone J Abbott J Shelmerdine, et al. 2007 Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus Arthritis Rheum 57 972 979 10.1002/art.22881 17665467 The development and validation process of a self-report (patient-derived items) lupus-specific measure (LupusQoL) in a predominantly female and Caucasian SLE population from the United Kingdom is described
23. M Jolly AS Pickard C Wilke, et al. 2010 Lupus-specific health outcome measure for US patients: the LupusQoL-US version Ann Rheum Dis 69 29 33 10.1136/ard.2008.094763 1:STN:280:DC%2BD1MfhsFSrtQ%3D%3D 19126561 The first SLE-specific HRQoL instrument modified and validated for use in an ethnically diverse US population is described. Satisfactory psychometric properties are presented
24. M Jolly AS Pickard L Fogg, et al. 2008 US patient derived lupus-specific patient reported outcome measure (Lupus-PRO©): validity and reliability Arthritis Rheum 58 9S S805 The validity and reliability of the LupusPRO in an ethnically heterogeneous US population are presented
25. Yu EB, Shikiar R, Howard K, et al.: Validation of LUP-QOL: a lupus-specific measure of health-related quality of life (HRQL) [abstract 0499]. Ann Rheum Dis 2006, 65(Suppl II).
26. LN Moorthy MG Peterson M Baratelli, et al. 2007 Multicenter validation of a new quality of life measure in pediatric lupus Arthritis Rheum 57 1165 1173 10.1002/art.22988 17907234 The development and validation of SMILEY as a brief, easily understood, valid, and reliable pediatric, SLE-specific QoL scale are described
27. LN Moorthy MG Peterson MJ Baratelli, et al. 2010 Preliminary cross-cultural adaptation of a new pediatric health-related quality of life scale in children with systemic lupus erythematosus: an international effort Lupus 19 83 88 10.1177/0961203309345770 1:STN:280:DC%2BC3c%2FgslWiug%3D%3D 19934176
28. DE Beaton C Bombardier F Guillemin MB Ferraz 2000 Guidelines for the process of cross-cultural adaptation of self-report measures Spine (Phila Pa 1976) 25 3186 3191 1:STN:280:DC%2BD3M7jt1Cmug%3D%3D
29. KJ Colangelo JE Pope C Peschken 2009 The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36 J Rheumatol 36 2231 2237 10.3899/jrheum.090193 19723907 This was a Canadian study addressing the concept of the minimally important difference in patients with SLE. This minimally important difference may differ bidirectionally depending on the measured outcome (specific values for the MCS and PCS scores of the SF-36 are provided)
30. KO Kong HJ Ho HS Howe, et al. 2007 Cross-cultural adaptation of the Systemic Lupus Erythematosus Quality of Life Questionnaire into Chinese Arthritis Rheum 57 980 985 10.1002/art.22911 17665463
31. M Jolly AS Pickard C Wilke, et al. 2007 Development and validation of a US lupus specific patient reported outcome measure Arthritis Rheum 56 9S S113
32. HM Bastian JM Roseman G McGwin Jr, et al. 2002 Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis Lupus 11 152 160 10.1191/0961203302lu158oa 1:STN:280: DC%2BD383msFaltg%3D%3D 12004788
33. S Durán M Apte GS Alarcón 2007 LUMINA Study Group: poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups J Natl Med Assoc 99 1196 1198 17987925 This carefully written review emphasizes the role of poor SES (poverty) in the increased mortality rates observed in patients with SLE
34. B Kuriya DD Gladman D Ibañez MB Urowitz 2008 Quality of life over time in patients with systemic lupus erythematosus Arthritis Rheum 59 181 185 10.1002/art.23339 18240183 In this study, SF-36 scores changed little over time (during an 8-year period); these changes were not affected by disease activity, glucocorticoid exposure, or accrued damage but were affected by the concomitant presence of fibromyalgia
35. AE Clarke P Panopalis M Petri, et al. 2008 SLE patients with renal damage incur higher health care costs Rheumatology (Oxford) 47 329 333 10.1093/rheumatology/kem373 1:STN:280:DC%2BD1c7hs1Wgtg%3D%3D
36. S Appenzeller AE Clarke P Panopalis, et al. 2009 The relationship between renal activity and quality of life in systemic lupus erythematosus J Rheumatol 36 947 952 10.3899/jrheum.080822 19369453 SLE patients with active renal disease had a slightly poorer QoL (physical subscales) than those without renal disease; however, it was not possible to accurately estimate whether a longitudinal change in renal disease activity was associated with a change in QoL.
37. CC Mok LY Ho MY Cheung, et al. 2009 Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study Scand J Rheumatol 38 121 127 10.1080/03009740802415527 1:STN:280:DC%2BD1M7psVynuw%3D%3D 18991189 This study evaluated and demonstrated the effects of persistent active disease and previous and new damage on the deterioration of SF-36 scores
38. A Dua DL Kamen AL Barnado, et al. 2009 Variable health-related quality of life among African American cohorts of patients with systemic lupus erythematosus Arthritis Rheum 60 10S S112 This was a comparative study of demographic and HRQoL variables in two African American SLE patient groups of different genetic admixtures and geographic locations (urban and rural). Significantly worse HRQoL was found among the urban African Americans than among their rural counterparts
39. ML Sanchez G McGwin Jr S Durán, et al. 2009 Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D Clin Exp Rheumatol 27 67 71 1:STN:280:DC%2BD1M3ktV2jsg%3D%3D 19327231 The SF-6D utility measure was used in this multiethnic study. Hispanic-Texan ethnicity and higher levels of social support were found to be positive predictors of HRQoL, whereas sociodemographic (older age, poverty) and disease-related (greater disease activity and damage, higher levels of fatigue, helplessness, and abnormal illness-related behaviors) variables were found to be negative predictors; prior SF-6D was found to be the strongest predictor of subsequent HRQoL
40. M Fernández GS Alarcón G McGwin Jr, et al. 2007 Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort Arthritis Rheum 57 986 992 10.1002/art.22908 17665468 In this multiethnic SLE cohort, the SF-6D was found to be associated with damage accrual, but not with mortality
41. E Freire A Bruscato R Ciconelli 2009 Quality of life in systemic lupus erythematosus patients in northeastern Brazil: is health-related quality of life a predictor of survival for these patients? Acta Reumatol Port 34 207 211 19474775
42. F Wolfe K Michaud T Li RS Katz 2010 EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia J Rheumatol 37 296 304 10.3899/jrheum.090778 20032098 This was a large comparison study of the EQ-5D and SF-36 (1316 SLE patients vs 13,722 rheumatoid arthritis, 3623 with noninflammatory rheumatic disorders, and 2733 with fibromyalgia). No differences in the EQ-5D and PCS scores among patients with these diseases were found. The MCS of the SF-36 was found to be lower in SLE than in rheumatoid arthritis and noninflammatory rheumatic disorders; poor QoL in SLE was predicted by disease damage and the number of comorbid events
43. S Khanna H Pal RM Pandey R Handa 2004 The relationship between disease activity and quality of life in systemic lupus erythematosus Rheumatology (Oxford) 43 1536 1540 10.1093/rheumatology/keh376 1:STN:280: DC%2BD2crpt1WqsQ%3D%3D
44. R Klein S Moghadam-Ki J LoMonico, et al. 2009 Quality of life in cutaneous lupus erythematosus Arthritis Rheum 60 10S S107
45. M Jolly AS Pickard R Mikolaitis, et al. 2007 Disease activity, body image and health status in Lupus Arthritis Rheum 56 S454
46. C Grootscholten G Ligtenberg RH Derksen, et al. 2003 Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist Qual Life Res 12 635 644 10.1023/A:1025176407776 1:STN:280:DC%2BD3svos1yktQ%3D%3D 14516173
47. C Grootscholten FJ Snoek M Bijl, et al. 2007 Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial J Rheumatol 34 1699 1707 1:CAS:528:DC%2BD2sXhtVSkt7bK 17659757 This small study compared the treatment effect of cyclophosphamide pulses plus oral prednisone versus azathioprine combined with intravenous methylprednisolone during a 24-month period on HRQoL in 87 predominantly Caucasian patients with proliferative LN. The study showed that aggressive treatment with immunosuppressive drugs and concomitant glucocorticoids improves HRQoL, especially in the first year
48. KB Dussán L Magder RA Brodsky, et al. 2008 High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures Lupus 17 1079 1085 10.1177/0961203308093828 19029275 In this small randomized controlled trial, high-dose cyclophosphamide was compared with monthly intravenous cyclophosphamide in first-time cyclophosphamide users. Improvement in several components of the SF-36 was demonstrated at 6 months in the high-dose cyclophosphamide patient group, but equal improvement in the two arms was demonstrated at 36 months
49. MM Medeiros AP Menezes VA Silveira, et al. 2008 Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy Eur J Intern Med 19 122 128 10.1016/j.ejim.2007. 06.012 1:CAS:528:DC%2BD1cXhtlyms74%3D 18249308
50. SS Uppal SJ Hayat R Raghupathy 2009 Efficacy and safety of infliximab in active SLE: a pilot study Lupus 18 690 697 10.1177/0961203309102557 1:CAS:528:DC%2BD1MXptVOjtb4%3D 19502264
51. M Jolly D Sandler W Sequeira, et al. 2009 Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus Arthritis Rheum 60 10S S108 The beneficial effects of hydroxychloroquine in preventing major lupus flares, retarding damage accrual, and improving patient survival are well-known; however, no demonstrable effect of hydroxychloroquine on the LupusQoL-US or the LupusPRO could be demonstrated in this study
52. GS Alarcón G McGwin AM Bertoli, et al. 2007 Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort Ann Rheum Dis 66 1168 1172 10.1136/ard.2006.068676 17389655
53. H Ito T Matsuno T Hirayama, et al. 2007 Health-related quality of life in patients with systemic lupus erythematosus after medium to long-term follow-up of hip arthroplasty Lupus 16 318 323 10.1177/0961203307077989 1:STN:280:DC%2BD2szmt1aisw%3D%3D 17576732
54. J Alvarez-Nemegyei A Bautista-Botello J Dávila-Velázquez 2009 Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases Clin Rheumatol 28 547 551 10.1007/s10067-008-1082-y 19139949
55. EW Karlson MH Liang H Eaton, et al. 2004 A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus Arthritis Rheum 50 1832 1841 10.1002/art.20279 15188360